Inactivated influenza vaccination is recommended by the Australian Technical Advisory Group on Immunisation for all children aged ≥6 months. Despite this recommendation, influenza vaccine was provided free of charge in 2017, under the National Immunisation Program (NIP), only to indigenous children aged 6-59 months and all children aged ≥6 months with comorbid conditions predisposing them to severe outcomes after influenza infection [8] . In a single state, Western Australia, a state-funded program has provided free influenza vaccine to all children 6-59 months of age from 2008 [9] [10] [11] .
The [12] . Vaccines distributed for children in 2017 included FluQuadri Junior and FluQuadri (Sanofi-Aventis; FluQuadri Junior provided for children aged 6-35 months) and Fluarix Tetra (GlaxoSmithKline; recommended for children aged ≥3 years) [12] . Live attenuated influenza vaccine has not been available in the Southern Hemisphere.
Previous studies have demonstrated that the Southern Hemisphere inactivated influenza vaccine is protective against influenza in children [13, 14] . The Western Australian Influenza Vaccine Effectiveness study previously estimated the vaccine effectiveness (VE) of TIV against any laboratory-confirmed influenza at 64.7% (95% confidence interval [CI], 33.7%-81.2%) among children aged 6-59 months attending a pediatric emergency department [9] . The PAEDS-FluCAN collaboration has previously demonstrated a VE of 55.5% (95% CI, 11.6%-77.6%) against hospitalization in children in 2014 [7] .
In this article, we describe the epidemiology of hospitalization in children presenting to Australian sentinel sites with confirmed influenza, identify predictors for severe disease (intensive care unit [ICU] admission and prolonged length of hospital stay [LOS] ), and describe vaccine coverage and VE estimates for the 2017 inactivated quadrivalent influenza vaccine.
METHODS

Study Design
FluCAN is a national hospital-based surveillance system recruiting patients with laboratory-confirmed influenza from 15 sentinel sites in Australia [4] . In 2017, additional surveillance sites from the PAEDS network joined the surveillance network, including 5 large specialty pediatric hospitals-Children's Hospital at Westmead (New South Wales), Lady Cilento Children's Hospital (Queensland), Monash Children's Hospital (Victoria), Princess Margaret Hospital (WA), and Women and Children's Hospital (South Australia)-and a large general hospital with an established pediatric unit, Royal Darwin Hospital (Northern Territory). In addition, pediatric patients from other participating FluCAN hospitals were also enrolled; these included Alice Springs (Northern Territory), Cairns Base Hospital (Queensland), Canberra Hospital (Australian Capital Territory), Geelong Hospital (Victoria), and Royal Hobart Hospital (Tasmania).
An influenza case patient was defined as a patient (aged ≤16 years) admitted to the hospital with an acute respiratory illness (ARI) and influenza confirmed by nucleic acid testing. Influenza testing was initiated by clinicians based on local guidelines. All influenza cases were confirmed using real-time reverse-transcription polymerase chain reaction (PCR) assays with standard primers. Subtype and lineage were not routinely determined in all laboratories. All tests were performed in local or referral laboratories accredited by the National Association of Testing Authorities. An ARI was defined by the presence of new respiratory symptoms including cough, shortness of breath or rhinorrhea. A hospital admission was defined as requiring inpatient care outside the emergency department.
Prospective clinician-led surveillance was conducted during the 2017 Southern Hemisphere influenza season (April to October; follow-up continuing to the end of November) using a detailed case-report form. Admission to an ICU was recorded, as well as risk factors predisposing to severe outcomes, including race (indigenous or nonindigenous) and the presence of underlying conditions (hereafter referred to as comorbid conditions) [8] . The comorbid conditions assessed included congenital heart disease, chronic respiratory and neurological disorders, immunocompromising conditions, and chronic illnesses, such as diabetes mellitus and renal failure [8] .
Influenza Complications and Management
We used multivariable regression to examine factors associated with ICU admission. Factors independently associated with ICU admission were determined using a logistic regression model with no variable selection process, because all factors were plausibly related to ICU admission. Factors associated with LOS were modeled using a negative binomial regression, and adjusted LOS ratios were calculated using the exponential of the LOS regression coefficient. Presentation delay was defined as the time from onset of illness to hospital admission. Treatment delay was defined as the time from onset of illness to oseltamivir prescription (in patients who received treatment). Patients were categorized into those who (1) did not receive oseltamivir, (2) received oseltamivir within 2 days of symptom onset, or (3) received oseltamivir >2 days after symptom onset.
Estimation of Vaccination Coverage and Effectiveness
Vaccination status was obtained from the medical record and by parental report and confirmed with the national Australian Immunisation Register [15] . Immunized was defined as receipt of ≥1 dose of a licensed influenza vaccine before presentation. Vaccination coverage was estimated in control patients ≥6 months of age admitted with ARI and testing negative for influenza with PCR.
We used an incidence density test-negative design to estimate VE, wherein controls were selected from among influenza-test negative subjects with ARI and tested contemporaneously with case patients; controls could test negative for all pathogens or have an alternative respiratory pathogen detected [16] [17] [18] . The VE was estimated as 1 minus the odds ratio of vaccination in influenza-positive case patients compared to test-negative control patients using methods described elsewhere [4, 19] . Only children ≥6 months of age and tested within 7 days of admission were included in VE estimates.
A conditional logistic regression model using influenza case status as the dependent outcome was constructed from influenza vaccination. The model was adjusted for potential confounders (age group [6-11 months, 12-23 months, and 2-4, 5-9, and ≥10 years], indigenous status, and comorbid conditions) and stratified by site and month of illness. Sensitivity analyses were performed by (1) restricting the cohort to children ≥6 months of age tested within 7 days of symptom onset and (2) excluding those whose symptoms onset occurred within 14 days of vaccination. Analyses were performed using Stata 14 software for Windows (StataCorp). Ethics approval has been obtained at all participating sites and Monash University.
RESULTS
Recruitment
During the period 2 April to 31 October 2017, a total of 1268 children were admitted with PCR-confirmed influenza to 11 hospitals (Table 1 ). The peak rate of admission was in late August (weeks 34-35; Supplementary Figure 1 ). Of these 1268 children, 400 (31.5%) were <2 years of age, 105 (8.3%) were indigenous, and 572 (45.1%) had underlying comorbid conditions (Tables 1 and 2 ).
Presentation and Treatment
In 1192 patients with confirmed influenza in whom the duration of symptoms was known, the median duration of symptoms before admission was 3 days (interquartile range, 1-5 days). A subset of 42 cases (3.3%) were diagnosed ≥7 days after hospital admission and therefore were likely to be hospital acquired. Only 199 patients with influenza (15.9%) received oseltamivir; of these, 82 patients (6.6% of the total) were known to have received oseltamivir within 48 hours of symptom onset.
Of all influenza case patients, 184 (14.5%) were admitted to the ICU. Young infants (aged <6 months; OR, 1.97; 95% CI, 1.21-3.20; P = .006) and those with comorbid conditions (2.29; 1.60-3.26; P < .001) were at increased odds of ICU admission ( Table 3 ). The rate of ICU admission was not influenced by indigenous status, influenza type, or vaccination status.
Outcomes
The median LOS was 3 days (interquartile range, 1-5 days), and the mean LOS was 4.6 days. LOS was prolonged in indigenous patients (adjusted LOS ratio, 1.51; 95% CI, 1.19-1.92; P = .001), those admitted to the ICU (3.45; 2.94-4.05; P < .001), children with comorbid conditions (1.34; 1.11-1.61; P = .002), and those receiving antivirals (1.76; 1.25-2.47; P = .001). Vaccination status was not associated with increased LOS In-hospital death was reported in 4 children (0.3%), ranging in age from <1 month to 13 years. Death occurred 20-43 days after influenza diagnosis. Three children had preexisting comorbid conditions and all required ICU admission for respiratory support Table 1 and/or extra corporal membrane oxygenation. One child died of Staphylococcus aureus pneumonia related to influenza infection (0.07%), with other deaths unrelated to influenza infection.
Vaccine Coverage
Vaccine coverage for all children >6 months of age ( Figure 1 and Table 4 ), was low. Of the 551 children who tested negative for influenza within 7 days after onset of illness, only 94 had received ≥1 dose of vaccine in 2017 (17.1%; 95% CI, 13.9%-20.2%; Figure 2 ). Despite a funded influenza program, vaccine coverage remained poor in WA children, with vaccination in only 24.4% (95% CI, 10.7%-38.1%) of test-negative children aged 6-59 months (national average, 14.8%; 11.7%-18.5%). No significant difference between states were observed ( Figure 2A ).
Vaccine coverage in influenza test-negative children with comorbid conditions ranged from 31.6% in WA to 22.9% in South Australia ( Figure 2B ). Vaccine coverage was increased in older children with comorbid conditions (33.0% in children aged ≥5 years vs 19.8% in those aged 6-23 months; Figure 2C ). Vaccine coverage was higher in indigenous children (30.0%; 95% CI, 12.6%-47.4%) than in nonindigenous children (16.5%; 13.1%-19.4%). In the age group eligible for funded vaccine (indigenous children aged 6-59 months), vaccine coverage was significantly higher in indigenous children (38.1%; 95% CI, 15.4%-60.7%) than in nonindigenous children (13.5%; 10.1%-16.9%; P < .01), but overall vaccination coverage was low.
VE Findings
After adjustment for age group, comorbid conditions, and indigenous status, VE was estimated as 30.3% (95% CI, 2.6%-50.2%; Table 5 ). VE did not differ by infecting type (Table 5 ; influenza A, 28.7% [95% CI, −3.0% to 50.6%]; influenza B, 32.3% [−11.2% to 58.8%]). Low VE was also demonstrated in children with comorbid conditions. By restricting the cohort to those tested within 7 days after symptom onset, VE was estimated to be 24.3% (95% CI, −7.1% to 46.6%). After exclusion of those vaccinated within 14 days of symptom onset, VE was estimated to be 31.7% (95% CI, 2.9%-51.9%).
DISCUSSION
We report on the largest and most comprehensive Australian study to date of pediatric influenza detailing data from 11 sentinel sites. Inclusion of tertiary pediatric hospitals (from the separate PAEDS network [6] ) into the existing FluCAN sentinel system has allowed us to report on influenza in 1268 hospitalized children, inclusive of metropolitan and regional hospitals, specialist pediatric hospitals, and hospitals in tropical and subtropical regions. By collecting data on control patients testing negative for influenza, vaccine coverage (particularly in vulnerable patients) and effectiveness against severe influenza has been accurately estimated [20] . These data demonstrate that the majority of Australian children requiring hospital admission with influenza are aged <5 years (57.8%) and have no comorbid conditions (54.9%). Of those hospitalized in 2017, 14% were admitted to the ICU and the in-hospital case fatality rate was 0.3%. Despite a significant increase in influenza activity in all age groups in the majority of Australian states in 2017 [21] , pediatric influenza outcomes seem similar to those observed in previous years (ICU admission, 11% in 2014 and 10% in 2009; case fatality rate, 0.3% and 0.9%, respectively [5, 7] .) Indigenous children were overrepresented in influenza-associated admissions (8.3% of the total influenza-positive population compared with the national average of 4.4% [22] ), as were children with comorbid conditions (45.1% of the total influenza positive population). These data highlight the ongoing significant burden of influenza in childhood and impact on healthcare systems.
The FluCAN network has reported VE in Australian adults since 2010 but has lacked sufficient recruitment to report separate pediatric VE estimates [19, 20, 23, 24] . The addition of large pediatric sites to the network has enabled calculation of VE against hospitalized influenza for children aged ≤16 years. In a 2014 pilot study, including 2 PAEDS sites, pediatric VE was estimated at 55% (95% CI, 12%-77%), comparable to the VE observed in hospitalized adults in the same year (51%; 42%-60%] [7] ). Likewise, the 2017 pediatric VE point estimate (30%; 95% CI, 3%-50%) is comparable to that observed in hospitalized adults (23%; 7%-36%) [25] . These data highlight that VE estimates in children and adults are comparable, providing further evidence of the effectiveness of inactivated vaccines against hospitalized influenza in childhood. In 2017, Australia experienced record high influenza disease notifications in all age groups [21] . Data from the PAEDSFLuCAN collaboration and other surveillance data have been used by policy makers in states and territories to justify the provision of funded preschool influenza vaccination in 2018. Through these programs, it is anticipated that national influenza vaccine coverage will significantly improve. As the most effective influenza prevention strategy available, vaccination is likely to have a direct impact on the burden of disease in children and potentially an impact on influenza burden more broadly through indirect effects [26] [27] [28] . The overall benefits of such a program will continue to be influence by the variable and moderate VE observed with inactivated seasonal influenza vaccines.
The findings of this study highlight ongoing and future challenges with childhood influenza vaccination in Australia.
Despite existing funding arrangements, vaccine coverage in children with comorbid conditions, indigenous children, and children aged 6-59 months in WA remains inadequate. Free vaccination has been provided through the NIP for children with comorbid conditions from 2010, yet coverage in those with comorbid conditions has not significantly changed since 2009 [5] , remaining well below that observed in adults with risk factors (2015 estimates, 80.2% in elderly adults and 57.9% in nonelderly adults with comorbid conditions [24] ).
Indigenous Australians are at increased risk of hospital admission with influenza; national hospitalization discharge data indicate that indigenous children aged <5 years are hospitalized with influenza more than twice as frequently as their nonindigenous peers [29] . This finding previously prompted the inclusion of indigenous children <5 years of age as eligible for NIP-funded influenza vaccination from 2015 onward; coverage achieved with this program in 2017 continues to be inadequate.
In 2017, vaccine coverage in WA, the only state with a funded universal vaccination program for children aged 6-59 months, remained suboptimal. One-dose coverage of >50% was initially observed in this age group in WA when introduced in 2008, yet coverage plummeted after suspension of the program in 2010 after adverse events with 1 brand of influenza vaccine were identified [30, 31] . Despite ongoing attempts to improve coverage in WA children, coverage remains inadequate. Parents cite ongoing concerns about safety and adverse effects, despite extensive postmarketing surveillance data demonstrating low rates of adverse events [9, [32] [33] [34] [35] . As Australia moves to improve influenza vaccination coverage in children in 2018, ongoing safety monitoring and community engagement is paramount to the success of such a program [34] .
As demonstrated in 2014, antiviral medications are infrequently used in Australian children with influenza [7] . Early clinical trials demonstrated more rapid resolution of symptoms and reduced shedding when neuraminidase inhibitors were used early in the illness [36] . Although controversial, results of individual patient-level meta-analysis suggest that neuraminidase inhibitors used in seasonal influenza, including oseltamivir, reduce illness duration, hospitalizations, and respiratory complications [37] . Early use is expected to have greater impact than delayed prescription. Antivirals are currently recommended in national antimicrobial guidelines, regardless of symptom duration, for all individuals with established influenza-associated complications and for patients requiring admission to the hospital [38] . The finding that oseltamivir receipt was associated with prolonged LOS needs to be interpreted cautiously in the current study owing to previously demonstrated residual confounding by severity of illness [39] . Future work should focus on ways to improve antiviral use, particularly among children with risk factors for severe influenza.
This study has a number of limitations. The decision to test was left to the treating clinician using local guidelines. The impact of this factor is expected to be small, because influenza tests are routinely recommended for infection control purposes in Australian children requiring hospital admission with acute respiratory symptoms. Delayed presentations or secondary bacterial pneumonia may be associated with false-negative influenza test results, as the influenza infection may be cleared at the time of presentation. It remains possible, although unlikely, that the decision to test might have been influenced by vaccination status.
In this study, we considered receipt of ≥1 dose of vaccine to equal fully vaccinated despite recommendations for children aged <9 years of age to receive 2 doses in the first vaccination year [8] . As in all observational studies, a biased VE estimate may result from unmeasured confounding or misascertainment of vaccination status or outcome. Influenza subtyping was not available for the majority of patients, limiting our ability to determine the relative burden of influenza A types and calculate accurate VE estimates by strain. Furthermore, the antigenic characteristics of influenza viruses from case patients was not performed, and we are therefore unable to determine the relatedness of circulating strains with influenza strains included in the 2017 seasonal vaccine.
Low vaccine uptake was also a major limitation affecting our ability to more precisely calculate VE. Inclusion of many, but not all, pediatric hospitals precludes estimation of the population at risk and thus the incidence of hospitalized influenza; based on previous estimates from 2 states, we estimate that this represents 20%-40% of pediatric influenza admissions nationally in 2017 [40] . Despite these limitations, the current study remains the largest and most comprehensive to date on pediatric influenza during a single season in Australia.
In summary, we describe >1200 children hospitalized with seasonal influenza in Australia, of whom 14% required ICU admission. Quadrivalent influenza vaccine seemed to be protective in 2017, but VE was lower than previous estimates. With all states introducing funded pediatric influenza vaccine programs in 2018, additional efforts to promote vaccination are required. The PAEDS-FLuCAN Network is uniquely placed to monitor the effectiveness of these programs against outcomes of public health importance. support from the National Health and Medical Research Council (partnership grant APP1113851 in support of PAEDS and fellowships to C. C. B., H. S. M., and A. C. C.), 
